AMENDMENTS TO THE SPECIFICATION:

Please replace paragraph 87 on page 30 with the following amended paragraph:

[0087] The CTL line EM71-1 was derived from a child prenatally infected with HIV-1, by repeated stimulations of PBMC with irradiated autologous B-EBV cells coated with the p17 Gag peptide SLYNTVATL (SEQ ID NO:1) (SL9, originally described by 44) in the presence of allogeneic irradiated PBMCs. Peptide recognition was HLA-A2 restricted (SD50: 0.5 ng/ml in ^{51}Cr assays). This epitope is present in HIV_{BRU}, HIV_{MN} and HIV_{JRCSF} strains and in HIV-vector.

Please replace paragraph 89 on page 31 with the following amended paragraph:

[0089] An HLA-A2+ CTL line (EM45) was derived from another HIV+ patient by stimulation with SL9 peptide. EM45 cells behave similarly as EM71-1 cells in HIV-1 virions cross-presentation assays (not shown). The CTL clone 141 (ref. [32]) recognized the p24 Gag epitope QASQEVKNW (SEQ ID NO:2) (QW9) in an HLA-B53 restricted manner (F.B., unpublished results). This epitope is present in HIV_{NL43} and in HIV-vector.

Please replace paragraph 120 on page 46 with the following amended paragraph:

[0120] Immunized mice were sacrificed and spleens were removed 2 weeks after DNA-based immunization. Splenocytes were cultured (107 cells/well in 24-well plate) in 2 ml of a Minimum Essential Medium (α-MEM, Gibco, Cergy Pontoise, France) supplemented with 10 mM Hepes, non essential amino acids, 1 mM sodium pyruvate, antibiotics, glutamine (Gibco BRL, Cergy Pontoise, France), 0.05 mM β-mercaptoethanol, and 10% fetal calf serum (Myoclone, Gibco BRL). Splenocytes were stimulated with 1 µg/ml of HIV-1 p24 (Gag 62-76) peptide (GHQAAMQMLKETINEE) (SEQ ID NO:3) containing a H2d-restricted epitope (107). Five days later half of the medium was replaced with fresh medium and two days later cells were used as effectors for the measurement of specific cytolytic activity in a standard chromium release assay. The targets cells were $H\text{-}2^d$ murine mastocytoma cells (P815) pulsed with the HIV-1 p24 (Gag) $H\text{-}2^d$ restricted peptide (15 µg/ml), or P815 cells infected with a recombinant vaccinia virus encoding the HIV-1 Gag protein (rvv TG 1144, (96) at a multiplicity of infection (MOI) of 20/1. Unpulsed P815 cells or wild type vaccinia virus infected cells were used as control. Targets were labeled with ^{51}Cr (3.7 MBq/10^6 cells, Amersham, U.K.). After a 4 h incubation at 37°C, 50 µl of supernatants were collected and counted on a beta counter as described (54). Spontaneous and maximum releases were determined from targets incubated with either

medium alone or lysis buffer (5% Triton X-100, 1% SDS). Percentage of specific release was calculated as (experimental release--spontaneous release)/(maximum release--spontaneous release) X 100. The specific lysis was determined for each point in triplicate.

After page 80, and before page 81, insert the attached pages titled "SEQUENCE LISTING".